Active Ingredient History
Selinexor (KPT-330) is a first in class XPO1 antagonist being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Lymphoma, Large B-Cell, Diffuse (approved 2020)
Multiple Myeloma (approved 2019)
Amyloid (Early Phase 1)
Amyloidosis (Early Phase 1)
Astrocytoma (Phase 1/Phase 2)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Castration (Phase 2)
Colorectal Neoplasms (Phase 2)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Diabetic Foot (Phase 1/Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)
Drug Misuse (Phase 1/Phase 2)
Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Epstein-Barr Virus Infections (Phase 3)
Esophageal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 1)
Gastrointestinal Stromal Tumors (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Hamartoma (Phase 1)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Early Phase 1)
Leiomyosarcoma (Phase 1)
Leukemia (Phase 1/Phase 2)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Prolymphocytic (Phase 1)
Liposarcoma (Phase 3)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Maximum Tolerated Dose (Phase 1/Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Nerve Sheath Neoplasms (Phase 1)
Neurofibrosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Polycythemia Vera (Phase 2)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 1)
Respiratory Tract Infections (Phase 3)
Rhabdoid Tumor (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 1)
Sarcoma, Endometrial Stromal (Phase 1)
Sarcoma, Ewing (Phase 1)
Small Cell Lung Carcinoma (Phase 2)
Smoldering Multiple Myeloma (Phase 2)
Stomach Neoplasms (Phase 1)
Thymoma (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue